切换至 "中华医学电子期刊资源库"

中华卫生应急电子杂志 ›› 2024, Vol. 10 ›› Issue (04) : 207 -212. doi: 10.3877/cma.j.issn.2095-9133.2024.04.004

论著

广州市病毒学抑制失败HIV/AIDS患者的耐药特征及影响因素分析
李佳佳1,2, 李凌华1,2, 吕诗韵2, 冯凯2, 刘琳珊2, 钟海丹2, 颜婵2, 刘聪1,2,()   
  1. 1.510440 广东广州,广州医科大学附属市八医院、广州市传染病临床医学研究所
    2.510440 广东广州,广州医科大学附属市八医院感染病中心
  • 收稿日期:2024-07-10 出版日期:2024-08-18
  • 通信作者: 刘聪
  • 基金资助:
    国家自然基金(82302513)广州市科技计划项目(20220020285,2023A03J0801)2023 年-2025 年华英科研基金项目(HY202301C02)2021~2023年广州市医学重点学科(2022YFC2304803)

Characteristics of genotype drug resistance and influencing factors of HIV/AIDS patients with virology failure in Guangzhou

Jiajia Li1,2, Linghua Li1,2, Shiyun Lv2, Kai Feng2, Linshan Liu2, Haidan Zhong2, Chan Yan2, Cong Liu1,2,()   

  1. 1.Guangzhou Medical Research Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University,Guangzhou,510440, China
    2.Infectious Disease Center,Guangzhou Eighth People's Hospital,Guangzhou Medical University,Guangzhou 510440,China
  • Received:2024-07-10 Published:2024-08-18
  • Corresponding author: Cong Liu
引用本文:

李佳佳, 李凌华, 吕诗韵, 冯凯, 刘琳珊, 钟海丹, 颜婵, 刘聪. 广州市病毒学抑制失败HIV/AIDS患者的耐药特征及影响因素分析[J]. 中华卫生应急电子杂志, 2024, 10(04): 207-212.

Jiajia Li, Linghua Li, Shiyun Lv, Kai Feng, Linshan Liu, Haidan Zhong, Chan Yan, Cong Liu. Characteristics of genotype drug resistance and influencing factors of HIV/AIDS patients with virology failure in Guangzhou[J]. Chinese Journal of Hygiene Rescue(Electronic Edition), 2024, 10(04): 207-212.

目的

分析广州市发生病毒学抑制失败的艾滋病毒(HIV)感染者/艾滋病(AIDS)患者的基因型耐药特征,并探讨影响耐药的因素。

方法

回顾性分析2021 年3 月至2023 年3 月在广州市某感染门诊接受抗病毒治疗(ART)后发生病毒学抑制失败并有完整耐药分析报告的394例HIV/AIDS患者的临床资料,运用二元Logistics回归方法分析耐药发生的影响因素。

结果

152例发生了耐药,耐药发生率为38.6%。其中分别有106 例(26.9%)、115 例(29.2%)、10 例(2.5%)和3 例(0.8%)患者对核苷酸逆转录酶抑制剂(NRTIs)、非核苷酸类逆转录酶抑制剂(NNRTIs)、蛋白酶抑制剂(PIs)和整合酶抑制剂(INSTIs)耐药。100例(65.8%)患者出现对拉米夫定(3TC)、恩曲他滨(FTC)的中高度耐药。分别有108例(71.1%)和94例(61.8%)患者对奈韦拉平(NVP)和依非韦伦(EFV)中高度耐药。多因素Logistic分析显示,基线CD4+T淋巴细胞计数≤200个/μL、近期CD4+T淋巴细胞计数≤200个/μL、201~399个/μL、耐药检测时HIV 病毒载量≥1000copies/mL 是耐药发生的危险因素。

结论

广州市ART 后发生病毒学失败的HIV/AIDS 患者耐药情况复杂,耐药位点多样,低CD4+T 淋巴细胞计数和高HIV 病毒载量是发生耐药的危险因素。

Objective

To analyze the genotype resistance characteristics of HIV/AIDS patients who had failed virology in Guangzhou, and to explore the factors affecting the occurrence of drug resistance.

Methods

The clinical data of HIV/AIDS patients who failed virology and had a complete drug resistance report after antiretroviral therapy (ART) were retrospectively analyzed in an infection clinic in Guangzhou from March 2021 to March 2023 and the binary logistics regression method was used to analyze the incidence of drug resistance.

Results

A total of 394 patients with virological failure were included, of which 152 developed resistance, resulting in a resistance rate of 38.6%. Among these, 106 cases (26.9%),115 cases (29.2%), 10 cases (2.5%), and 3 cases (0.8%) exhibited resistance to nucleoside reverse transcriptase inhibitors (NRTIs), non - nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase inhibitors (INSTIs), respectively. Additionally, 100 cases (65.8%) showed moderate to high resistance to lamivudine (3TC) and emtricitabine (FTC). Furthermore, 108 cases (71.1%)and 94 cases (61.8%) showed moderate to high resistance to nevirapine (NVP) and efavirenz (EFV),respectively. Multi-factor logistic analysis showed that the baseline CD4+ T lymphocyte count was ≤200/μL,recent CD4+ T lymphocyte count was ≤200/μL, 201~399/μL,and HIV load was ≥1000 copies/ml during drug resistance detection, which were resistant risk factors for the occurrence of drug resistance.

Conclusion

HIV/AIDS patients with virological failure after ART in Guangzhou are complex in drug resistance, and the drug resistance sites are diverse. Low CD4+T lymphocyte count and high HIV load are risk factors for drug resistance.

表1 广州市394例病毒学失败HIV/AIDS患者的基本情况[例(%)]
图1 152例耐药HIV/AIDS 患者的耐药位点突变率
图2 152例耐药HIV/AIDS患者不同抗病毒药物的耐药率
表2 病毒学失败HIV/AIDS患者耐药影响因素分析
[1]
中国疾病预防控制中心性病艾滋病预防控制中心.2023 年12月全国艾滋病性病疫情[J].中国艾滋病性病,2024,30(3):225.
[2]
Dou Z, Luo Y, Zhao Y, et al. Trends in mortality and prevalence of reported HIV/AIDS Cases-China, 2002-2021[J]. China CDC Wkly,2023,5(42):943-947.
[3]
World Health Organization. Global action plan on HIV drug resistance 2017-2021[EB/OL].[2024-07-10].https://iris.who.int/handle/10665/255883.
[4]
Zhou C, Kang R, Liang S, et al. Risk factors of drug resistance and the potential risk of HIV-1 Transmission of Patients with ART Virological Failure:a population-based study in sichuan,china[J].Infect Drug Resist,2021(14):5219-5233.
[5]
中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2021 年版)[J].协和医学杂志,2022,13(2):203-226.
[6]
WHO.HIV drug resistance-brief report 2024[EB/OL]. (2024-02-29)[2024-07-10].https://www.who.int/publications/i/item/9789240086319.
[7]
谢莹娜.赣州市抗逆转录病毒治疗失败患者HIV-1 基因型耐药研究[D].赣州:赣南医学院,2023.
[8]
周莹,卢静,张之,等.江苏省艾滋病一线药物抗病毒治疗失败病人的耐药特征及影响因素分析[J]. 中华疾病控制杂志,2017,21(12):1191-1194,1199.
[9]
Yu E, Xu YJ, Li M, et al. HIV-1 Subtype diversity and factors affecting drug resistance among patients with virologic failure in antiretroviral therapy in hainan province, China, 2014 - 2020[J].Biomed Environ Sci,2023,36(9):800-813.
[10]
Lu X,Zhao H,Zhang Y,et al.HIV-1 drug-resistant mutations and related risk factors among HIV - 1 - positive individuals experiencing treatment failure in Hebei Province, China[J]. AIDS Res Ther,2017,14(1):4.
[11]
Lan Y,Ling X,Deng X,et al.Drug resistance profile among hiv-1 infections experiencing ART with low - level viral load in guangdong China during 2011-2022: a retrospective study[J].Infect Drug Resist,2023(16):4953-4964.
[12]
Li CX, Li YY, He LP, et al. The predictive role of CD4+ cell count and CD4/CD8 ratio in immune reconstitution outcome among HIV/AIDS patients receiving antiretroviral therapy: an eight-year observation in China[J].BMC Immunol,2019,20(1):31.
[13]
Yang C, Yang S, Li J, et al. Genetic diversity and drug resistance among antiretroviral treatment-failed individuals from 2010 to 2012 in Honghe,China[J]. AIDS Res Hum Retroviruses,2015,31(8):822-829.
[14]
McCluskey SM, Siedner MJ, Marconi VC. Management of virologic failure and HIV drug resistance[J]. Infect Dis Clin North Am,2019,33(3):707-742.
[15]
龙海, 甘霖, 杨小燕, 等. 贵阳市266 例新发现HIV/AIDS 患者抗病毒治疗前HIV-1 耐药及亚型特征[J]. 中国艾滋病性病,2022,28(12):1350-1354.
[16]
Rhee SY, Taylor J, Fessel WJ, et al. HIV-1 protease mutations and protease inhibitor cross - resistance[J]. Antimicrob Agents Chemother,2010,54(10):4253-4261.
[17]
Labhardt ND, Ringera I, Lejone TI, et al. Effect of offering sameday art vs usual health facility referral during home-based hiv testing on linkage to care and viral suppression among adults with HIV in lesotho: the CASCADE randomized clinical trial[J].JAMA,2018,319(11):1103-1112.
[18]
Luo X,Herzig E, Doitsh G, et al. HIV-2 depletes CD4 T cells through pyroptosis despite Vpx-dependent degradation of SAMHD1[J].J Virol,2019,93(24):e00619-e00666.
[19]
阮尉月清.云南省老年HIV/AIDS 患者抗病毒治疗失败基因型耐药相关研究[D].昆明:昆明医科大学,2022.
[1] 吴茜, 邓力, 练士贤, 张华, 江颖, 张宏伟. 伴人类免疫缺陷病毒感染乳腺癌患者的临床病理特征与预后的相关性研究[J]. 中华乳腺病杂志(电子版), 2023, 17(03): 151-156.
[2] 戚仕轩, 阮连国. 人类免疫缺陷病毒感染快速启动抗逆转录病毒治疗研究及模式探索[J]. 中华实验和临床感染病杂志(电子版), 2024, 18(04): 193-199.
[3] 曾雪灵, 杨思园, 常宇飞, 赵红心, 王凌航. 176例人类免疫缺陷病毒合并肺部感染者呼吸道病原体特点与免疫学特征[J]. 中华实验和临床感染病杂志(电子版), 2024, 18(03): 142-148.
[4] 叶俊杰, 胡波涌. 人类免疫缺陷病毒感染者限期骨折内植物手术并发症的影响因素[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(06): 423-430.
[5] 陈珂, 孙挥宇. 人类免疫缺陷病毒感染/获得性免疫缺陷综合征患者非感染性相关眼病研究进展[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(06): 395-399.
[6] 张玉, 薛文瑞, 王鑫, 李旭瑜, 王旭东, 袁鹏飞, 梁雨润, 韩志兴, 张海建, 刘庆军, 纪世琪. 人类免疫缺陷病毒感染合并膀胱癌14例临床特点[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 354-358.
[7] 崔贵香, 丁晓燕, 褚盈晖, 孙代, 吴海燕, 陈京龙. 57例人类免疫缺陷病毒感染合并Burkkit淋巴瘤患者的临床分析[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 102-109.
[8] 袁瑞, 胡文佳, 桂希恩, 严亚军, 冯玲, 柯亨宁, 熊勇, 杨蓉蓉. 淋巴细胞精细分型检测在人类免疫缺陷病毒感染者/获得性免疫缺陷综合征患者中的应用[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 84-91.
[9] 李倩, 邓莉平, 陈果, 张忠威, 莫平征, 胡文佳, 陈良君, 张捷, 张永喜, 杨蓉蓉, 熊勇. 宏基因组二代测序在获得性免疫缺陷综合征合并中枢神经系统感染中的临床应用[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 24-31.
[10] 汤艳芬, 赵雯, 马成杰, 刘刚, 陈奇, 刘菁, 薛天娇, 刘岩岩, 陈融佥, 王宇. 人类免疫缺陷病毒感染合并鸟分枝杆菌复合群病临床特点[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(05): 348-353.
[11] 魏春波, 万钢, 许东梅, 赵兴云, 袁柳凤, 吴焱, 伦文辉. 60例人类免疫缺陷病毒感染者/获得性免疫缺陷综合征合并神经梅毒患者临床和实验室特征[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(04): 254-260.
[12] 杜娟, 宋波, 颜晓明, 牛佳鸣, 林元龙, 陈晓红, 李锦, 梁晗, 张铮, 李宇欧, 王福祥, 邵冰. 外周血单个核细胞内人类免疫缺陷病毒DNA和RNA定量对病毒转录活性的区分[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(03): 165-171.
[13] 田飞, 高颂, 李铮, 王颖慧, 王媛媛. 1989至2020年北京市东城区1 076例人类免疫缺陷病毒感染者/获得性免疫缺陷综合征患者生存时间及影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(02): 100-107.
[14] 张燕珍, 王锡携, 文小兰. 血清巨噬细胞迁移抑制因子对活动性肺结核分诊检测的意义[J]. 中华肺部疾病杂志(电子版), 2023, 16(02): 200-202.
[15] 王希岗, 张波, 李鸣, 高敏, 薛建新. 神经外科手术部位感染在HIV感染者与非HIV感染者中的临床差异[J]. 中华神经创伤外科电子杂志, 2023, 09(04): 228-233.
阅读次数
全文


摘要